RPAM
FPRX

Rhenman & Partners Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-250,000
Closed -$4.25M – 95
2020
Q4 		$4.25M Buy
+250,000
New +$3.13M 0.35% 69

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Rhenman & Partners Asset Management's FPRX Position: Q1 2021 in Review

Rhenman & Partners Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 250,000 shares — an estimated $4.25M sold.

Rhenman & Partners Asset Management first reported a position in FPRX in Q4 2020 and held it in 1 quarter. The position peaked at $4.25M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Rhenman & Partners Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 250,000 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $4.25M.
  • Rhenman & Partners Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Five Prime Therapeutics, Inc. position peaked at $4.25M in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2021, filed 14 May 2021.